347. Active metabolite concentration of clopidogrel in patients taking different doses of aspirin results of the interaction trial 353. Real world variability in dabigatran levels in patients wit…
505. Recombinant soluble thrombomodulin in severe sepsis a systematic review and meta analysis 508. Recombinant human soluble thrombomodulin in severe sepsis a systematic review and meta analysis…
699. Anemia predicts thromboembolic events, bleeding complications and mortality in patients with atrial fibrillation insights from the RE-LY trial 708. Risk of ischemic stroke associated with non…
597. Targeting coagulation factor receptors - protease-activated receptors in idiopathic pulmonary fibrosis 608. Hematology journals do not sufficiently adhere to reporting guidelines: a systemati…
835. Ibrutinib-associated bleeding: pathogenesis, management adn risk reduction strategies 848. Long-term treatment of cancer-associated Thrombosis: the choice of the optimal anticoagulant 858. I…
1541. C-reative protein gene polymorphism preditct the risk of thromboboembolic stroke in patiens with atrial fibrillation a more than 10-year prospective follow-up study 1547. Assement of clinica…
1728. Minimal factor XIII activity level to prevent major spontaneous bleeds 1737. In silico evaluation of limited blood sampling strategies for individualized recombinant factor IX prophylaxis in…
1901. Qualification of a select one stage activated partial thromboplastin time based clotting assay and two chromogenic assays and two chromogenic assays for the post administration 1913. Effect …
2115. Effect of late prophylaxis in hemophilia on joint status a randomized trial 2125. Reversal of apixaban anticoagulation by four factor prothombin complex concetrates in healthy subjects a ran…
1241. Novel insight into the regulation of coagulation by factor V isoforms, tissue factors V isoforms tissue factor pathway inhibitor and protein s 1251. Diagnosis of acute pulmonary embolism 12…